They showed that this in vivo gene-editing strategy is effective in targeting hSOD1, resulting in a disease-free state in two different hSOD1-G93A transgenic mouse models (G1H and G1L) of ALS (Deng et al., 2021[19]). The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.